Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: a pooled analysis of clinical trials

Adequate adherence to hepatitis C virus (HCV) treatment is believed to be a key component of treatment success because non-adherence can potentially result in treatment failure and the emergence of resistant viral variants. This analysis assessed factors associated with non-adherence to glecaprevir/pibrentasvir (G/P) therapy and the impact of non-adherence on sustained virologic response at post-treatment week 12 (SVR12) rates in HCV genotype (GT) 1-6-infected patients.